Prestige Consumer Healthcare (PBH) 10-Q 1 Aug 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2019	Jul. 26, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2019
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,241,294

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenues
Total revenues	$ 232,154	$ 253,980
Cost of Sales
Cost of sales excluding depreciation	97,100	112,069
Cost of sales depreciation	987	1,288
Cost of sales	98,087	113,357
Gross profit	134,067	140,623
Operating Expenses
Advertising and promotion	34,801	37,111
General and administrative	21,706	23,941
Depreciation and amortization	6,074	7,084
Total operating expenses	62,581	68,136
Operating income	71,486	72,487
Other (income) expense
Interest income	(43)	(100)
Interest expense	25,063	26,040
Other expense, net	416	87
Total other expense	25,436	26,027
Income before income taxes	46,050	46,460
Provision for income taxes	12,125	11,994
Net income	$ 33,925	$ 34,466
Earnings per share:
Basic (in USD per share)	$ 0.66	$ 0.65
Diluted (in USD per share)	$ 0.65	$ 0.65
Weighted average shares outstanding:
Basic (in shares)	51,697	52,640
Diluted (in shares)	52,047	52,942
Comprehensive income, net of tax:
Currency translation adjustments	$ (224)	$ (2,974)
Total other comprehensive loss	(224)	(2,974)
Comprehensive income	33,701	31,492
Net sales
Revenues
Total revenues	232,133	253,954
Other revenues
Revenues
Total revenues	$ 21	$ 26

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Current assets
Cash and cash equivalents	$ 29,042	$ 27,530
Accounts receivable, net of allowance of $12,059 and $12,965, respectively	142,927	148,787
Inventories	129,388	119,880
Prepaid expenses and other current assets	9,164	4,741
Total current assets	310,521	300,938
Property, plant and equipment, net	51,387	51,176
Operating lease right-of-use asset	16,097	0
Goodwill	578,309	578,583
Intangible assets, net	2,501,358	2,507,210
Other long-term assets	3,038	3,129
Total Assets	3,460,710	3,441,036
Current liabilities
Accounts payable	62,109	56,560
Accrued interest payable	13,937	9,756
Operating lease liabilities, current portion	5,099	0
Other accrued liabilities	62,346	60,663
Total current liabilities	143,491	126,979
Long-term debt, net	1,779,380	1,798,598
Deferred income tax liabilities	403,750	399,575
Long-term operating lease liability, net of current portion	12,526	0
Other long-term liabilities	19,940	20,053
Total Liabilities	2,359,087	2,345,205
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,741 shares at June 30, 2019 and 53,670 shares at March 31, 2019	537	536
Additional paid-in capital	480,805	479,150
Treasury stock, at cost - 2,848 shares at June 30, 2019 and 1,871 shares at March 31, 2019	(89,493)	(59,928)
Accumulated other comprehensive loss, net of tax	(25,971)	(25,747)
Retained earnings	735,745	701,820
Total Stockholders' Equity	1,101,623	1,095,831
Total Liabilities and Stockholders' Equity	$ 3,460,710	$ 3,441,036

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 12,059	$ 12,965
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,741,000	53,670,000
Treasury stock (in shares)	2,848,000	1,871,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Retained Earnings (Accumulated Deficit)
Equity, beginning balance at Mar. 31, 2018	$ 1,178,610	$ 534	$ 468,783	$ (7,669)	$ (19,315)	$ 736,277
Common stock, beginning balance (in shares) at Mar. 31, 2018		53,396,000
Treasury stock, beginning balance (in shares) at Mar. 31, 2018				353,000
Stock-based compensation	1,657		1,657
Exercise of stock options	$ 880		880
Exercise of stock options (in shares)	32,800	33,000
Issuance of shares related to restricted stock	$ 0	$ 2	(2)
Issuance of shares related to restricted stock (in shares)		174,000
Treasury share repurchases	$ (52,259)			$ (52,259)
Treasury share repurchases (in shares)	1,449,750			1,518,000
Net income	$ 34,466					34,466
Other comprehensive income (loss)	(2,974)				(2,974)
Equity, ending balance at Jun. 30, 2018	1,161,723	$ 536	471,318	$ (59,928)	(22,289)	772,086
Common stock, ending balance (in shares) at Jun. 30, 2018		53,603,000
Treasury stock, ending balance (in shares) at Jun. 30, 2018				1,871,000
Equity, beginning balance at Mar. 31, 2019	$ 1,095,831	$ 536	479,150	$ (59,928)	(25,747)	701,820
Common stock, beginning balance (in shares) at Mar. 31, 2019		53,670,000
Treasury stock, beginning balance (in shares) at Mar. 31, 2019	1,871,000			1,871,000
Stock-based compensation	$ 1,381		1,381
Exercise of stock options	$ 275		275
Exercise of stock options (in shares)	9,300	9,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Issuance of shares related to restricted stock (in shares)		62,000
Treasury share repurchases	$ (29,565)			$ (29,565)
Treasury share repurchases (in shares)	949,825			977,000
Net income	$ 33,925					33,925
Other comprehensive income (loss)	(224)				(224)
Equity, ending balance at Jun. 30, 2019	$ 1,101,623	$ 537	$ 480,805	$ (89,493)	$ (25,971)	$ 735,745
Common stock, ending balance (in shares) at Jun. 30, 2019		53,741,000
Treasury stock, ending balance (in shares) at Jun. 30, 2019	2,848,000			2,848,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating Activities
Net income	$ 33,925	$ 34,466
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,061	8,372
Loss on disposal of property and equipment	20	1
Deferred income taxes	4,206	6,755
Amortization of debt origination costs	851	920
Stock-based compensation costs	1,381	1,657
Non-cash operating lease cost	1,338	0
Changes in operating assets and liabilities:
Accounts receivable	5,808	(4,357)
Inventories	(8,939)	(9,303)
Prepaid expenses and other current assets	(4,335)	623
Accounts payable	5,306	16,479
Accrued liabilities	7,616	347
Operating lease liabilities	(1,368)	0
Other	(93)	(108)
Net cash provided by operating activities	52,777	55,852
Investing Activities
Purchases of property, plant and equipment	(1,956)	(2,469)
Net cash used in investing activities	(1,956)	(2,469)
Financing Activities
Borrowings under revolving credit agreement	15,000	20,000
Repayments under revolving credit agreement	(35,000)	(20,000)
Proceeds from exercise of stock options	275	880
Fair value of shares surrendered as payment of tax withholding	(799)	(2,281)
Repurchase of common stock	(28,766)	(49,978)
Net cash used in financing activities	(49,290)	(51,379)
Effects of exchange rate changes on cash and cash equivalents	(19)	(283)
Increase in cash and cash equivalents	1,512	1,721
Cash and cash equivalents - beginning of period	27,530	32,548
Cash and cash equivalents - end of period	29,042	34,269
Interest paid	19,966	20,907
Income taxes paid	$ 1,807	$ 334

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 2) to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 8. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2020 ) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three months ended June 30, 2019 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2020 . These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update amends a number of aspects of lease accounting, including requiring lessees to recognize all leases with a term greater than one year as a right-of-use ("ROU") asset and corresponding lease liability, measured at the present value of the lease payments. On April 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for the three months ended June 30, 2019 are presented under Topic 842. No prior period amounts were adjusted and the prior period continues to be reported in accordance with previous lease guidance, ASC Topic 840, Leases . The new standard provides a number of optional practical expedients in transition. We elected the package of transition provisions available for expired or existing contracts, which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697 ) $ (5,697 ) Long-term operating lease liabilities, net of current portion $ — $ (13,296 ) $ (13,296 ) Other accrued liabilities (1) $ (60,663 ) $ 1,558 $ (59,105 ) (1) Relates to deferred rent and exit costs associated with existing leases. Adoption of this accounting pronouncement had no impact on our other financial statements. See Note 6 for our lease accounting policy. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. These amendments clarify and improve areas of guidance related to recently issued standards on the topics of credit losses, hedging and recognition and measurements. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief , which provides entities that have certain instruments an option to irrevocably elect the fair value option in Subtopic 825-10. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Divestitures

Divestitures	3 Months Ended
	Jun. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures On July 2, 2018, we sold the Comet®, Spic and Span®, Chore Boy®, Chlorinol® and Cinch® brands, as well as associated inventory. These brands represented our Household Cleaning segment. As a result of this transaction, we received proceeds of approximately $65.9 million and recorded a pre-tax gain on sale of $1.3 million

Inventories

Inventories	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) June 30, 2019 March 31, 2019 Components of Inventories Packaging and raw materials $ 14,367 $ 17,082 Work in process 342 161 Finished goods 114,679 102,637 Inventories $ 129,388 $ 119,880 Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $5.6 million and $5.5 million at June 30, 2019 and March 31, 2019

Goodwill

Goodwill	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2019 Goodwill $ 711,104 $ 31,190 $ 742,294 Accumulated impairment loss (163,711 ) — (163,711 ) Balance - March 31, 2019 547,393 31,190 578,583 2020 Reductions: Effects of foreign currency exchange rates — (274 ) (274 ) Balance - June 30, 2019 Goodwill 711,104 30,916 742,020 Accumulated impairment loss (163,711 ) — (163,711 ) Balance - June 30, 2019 $ 547,393 $ 30,916 $ 578,309 Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. The date of our annual impairment review was February 28, 2019 , and we recorded impairment charges in our March 31, 2019 financial statements. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 28, 2019 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an additional impairment charge to be recorded in the future. As of June 30, 2019 , no events have occurred that would indicate further potential impairment of goodwill.

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (897 ) (63 ) (960 ) Balance — June 30, 2019 2,272,294 390,220 2,662,514 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 4,906 4,906 Effects of foreign currency exchange rates — (14 ) (14 ) Balance — June 30, 2019 — 161,156 161,156 Intangible assets, net - June 30, 2019 $ 2,272,294 $ 229,064 $ 2,501,358 Amortization expense was $4.9 million for the three months ended June 30, 2019 , and $5.8 million for the three months ended June 30, 2018 . Based on our amortizable intangible assets as of June 30, 2019 , amortization expense is expected to be approximately $14.7 million for the remainder of fiscal 2020 , $19.6 million in each of fiscal 2021 , 2022 , 2023 and 2024 and $135.9 million thereafter. Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. The date of our annual impairment review was February 28, 2019 , and we recorded impairment charges in our March 31, 2019 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record additional impairment charges in the future. As of June 30, 2019

Leases

Leases	3 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. These leases have lease terms of 1 to 10 years, some of which include options to terminate or extend leases for up to 1 to 6 years or on a month-to-month basis. The exercise of lease renewal options is at our sole discretion and our lease right-of-use assets and liabilities reflect only the options we are reasonably certain that we will exercise. We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether we have the right to control the identified asset. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. Variable lease payments, which do not vary based on an index or rate, are excluded from the ROU asset and lease liability determination. Variable lease payments are typically usage-based and are recorded in the period in which the obligation for those payments is incurred. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. As the implicit rate in our leases is unknown, we used our incremental borrowing rate based on the information available at the date of adoption for existing leases and at the lease commencement date for new leases in determining the present value of future lease payments. We give consideration to our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rates. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. For the measurement and classification of our lease agreements, we group lease and non-lease components into a single lease component for all underlying asset classes. We have also elected to exclude any leases within our existing classes of assets with a term of twelve months or less. The components of lease expense for the three months ended June 30, 2019 was as follows: (In thousands) Operating lease cost $ 1,216 Short term lease cost 23 Variable lease cost 16,599 Sublease income (914 ) Total net lease cost $ 16,924 As of June 30, 2019 , the maturities of operating lease liabilities were as follows: (In thousands) Year Ending March 31, 2020 (Remaining nine months ending March 31, 2020) $ 4,577 2021 3,450 2022 2,488 2023 1,794 2024 1,705 Thereafter 6,761 Total undiscounted lease payments 20,775 Less imputed interest (3,150 ) Total present value of lease payments $ 17,625 As of June 30, 2019 , the weighted average remaining lease term was 6.24 years and the weighted average discount rate used to determine the operating lease liability was 5.21% . The following table summarizes future minimum lease payments for our operating leases as of March 31, 2019, before adoption of ASC 842: (In thousands) Facilities Equipment Total Year Ending March 31, 2020 $ 2,828 $ 314 $ 3,142 2021 2,633 248 2,881 2022 2,265 213 2,478 2023 1,684 105 1,789 2024 1,705 — 1,705 Thereafter 6,780 — 6,780 $ 17,895 $ 880 $ 18,775 On May 13, 2019, we entered into a Master Logistics Services Agreement with GEODIS Logistics LLC (“GEODIS”), pursuant to which GEODIS will serve as a new third party logistics provider. The agreement will have an initial term of five years with an option to renew for an additional five year term. Under the Master Logistics Services Agreement, we have authorized GEODIS to lease a facility under a five year term. The lease commenced in July 2019 and the lease and non-lease components will be recorded in our second quarter fiscal year 2020 financial statements. The right-of-use asset and operating lease liability at lease commencement was approximately $20.5 million .

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) June 30, 2019 March 31, 2019 Accrued marketing costs $ 31,886 $ 31,228 Accrued compensation costs 5,701 10,958 Accrued broker commissions 1,057 1,361 Income taxes payable 5,640 88 Accrued professional fees 2,284 2,441 Accrued production costs 9,252 6,788 Other accrued liabilities 6,526 7,799 $ 62,346 $ 60,663

Long-Term Debt

Long-Term Debt	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt At June 30, 2019 , we had $55.0 million outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver") and an additional borrowing capacity of $102.7 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) June 30, 2019 March 31, 2019 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024. 738,000 738,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022. 55,000 75,000 Long-term debt 1,793,000 1,813,000 Less: unamortized debt costs (13,620 ) (14,402 ) Long-term debt, net $ 1,779,380 $ 1,798,598 As of June 30, 2019 , aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 5.375% senior unsecured notes due 2021 (the "2013 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2020 (remaining nine months ending March 31, 2020) $ — 2021 — 2022 455,000 2023 — 2024 1,338,000 Thereafter — $ 1,793,000

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB ASC 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at June 30, 2019 and March 31, 2019 . June 30, 2019 March 31, 2019 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 627,000 $ 600,000 $ 606,000 2013 Senior Notes 400,000 403,000 400,000 401,500 2012 Term B-5 Loans 738,000 733,388 738,000 728,775 2012 ABL Revolver 55,000 55,000 75,000 75,000 At June 30, 2019 and March 31, 2019

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through June 30, 2019 . During the three months ended June 30, 2019 and 2018 , we repurchased 26,264 shares and 68,939 shares, respectively, of common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the three months ended June 30, 2019 and 2018 were at an average price of $30.44 and $33.09 , respectively. All of the repurchased shares have been recorded as treasury stock. During the three months ended June 30, 2019 and 2018 , we also repurchased 949,825 shares and 1,449,750 shares, respectively, of our common stock in conjunction with our share repurchase program. The repurchases for the three months ended June 30, 2019 and 2018 were at an average price of $30.29 and $34.47 , respectively and totaled $28.8 million and $50.0 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Jun. 30, 2019
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at June 30, 2019 and March 31, 2019 : (In thousands) June 30, 2019 March 31, 2019 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (27,102 ) $ (26,878 ) Unrecognized net gain on pension plans 1,131 1,131 Accumulated other comprehensive loss, net of tax $ (25,971 ) $ (25,747 ) As of June 30, 2019 and March 31, 2019 , no

Earnings Per Share

Earnings Per Share	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and nonvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, (In thousands, except per share data) 2019 2018 Numerator Net income $ 33,925 $ 34,466 Denominator Denominator for basic earnings per share — weighted average shares outstanding 51,697 52,640 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 350 302 Denominator for diluted earnings per share 52,047 52,942 Earnings per Common Share: Basic earnings per share $ 0.66 $ 0.65 Diluted earnings per share $ 0.65 $ 0.65 For the three months ended June 30, 2019 and 2018 , there were 1.0 million and 0.8 million

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three months ended June 30, 2019 and 2018 , pre-tax share-based compensation costs charged against income were $1.4 million and $1.7 million , respectively, and the related income tax recognized was a benefit of $0.2 million and a benefit of $0.2 million , respectively. At June 30, 2019 , there were $11.0 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted average period of 1.1 years. The total fair value of options and RSUs vested during the three months ended June 30, 2019 and 2018 was $6.1 million and $10.7 million , respectively. For the three months ended June 30, 2019 and 2018 , we received cash from the exercise of stock options of $0.3 million and $0.9 million , respectively. For the three months ended June 30, 2019 and 2018 , we realized $0.4 million and $1.2 million , respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At June 30, 2019 , there were 1.4 million shares available for issuance under the Plan. On May 6, 2019, the Compensation and Talent Management Committee of our Board of Directors granted 98,644 performance stock units, 89,286 RSUs and stock options to acquire 281,487 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $30.56 per share, which was equal to the closing price for our common stock on the date of the grant. On May 13, 2019, the Compensation and Talent Management Committee of our Board of Directors granted 7,287 RSUs and stock options to acquire 21,194 shares of our common stock to a recently hired executive officer under the Plan. The stock options were granted at an exercise price of $30.19 per share, which was equal to the closing price for our common stock on the date of the grant. Restricted Stock Units RSUs granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three -year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017, 2018 and 2019, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors prior to fiscal 2020 vest immediately upon grant, and will be settled by delivery to the director of one share of our common stock for each vested RSU promptly following the earliest of the (i) director's death, (ii) director's disability or (iii) six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. See Note 19 for a description of RSUs granted to directors in July 2019. The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted Average Grant-Date Fair Value Three Months Ended June 30, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 203.8 29.46 Vested and issued (173.4 ) 43.00 Forfeited (31.1 ) 48.32 Vested and nonvested at June 30, 2018 392.8 36.68 Vested at June 30, 2018 90.5 29.88 Three Months Ended June 30, 2019 Vested and nonvested at March 31, 2019 413.0 $ 36.58 Granted 195.2 30.55 Vested and issued (61.8 ) 48.04 Forfeited (25.2 ) 36.85 Vested and nonvested at June 30, 2019 521.2 32.94 Vested at June 30, 2019 113.2 31.05 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of our common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the nonvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted average grant-date fair values of the options granted during the three months ended June 30, 2019 and 2018 were $10.83 and $10.22 , respectively. Three Months Ended June 30, 2019 2018 Expected volatility 30.9% - 31.3% 29.6 % Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 Risk-free rate 2.3% to 2.4% 2.9 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Three Months Ended June 30, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (32.8 ) 26.81 Forfeited or expired (72.7 ) 45.00 Outstanding at June 30, 2018 1,062.2 38.61 7.6 $ 6,573 Vested at June 30, 2018 599.8 37.99 6.2 $ 4,054 Three Months Ended June 30, 2019 Outstanding at March 31, 2019 944.6 $ 38.45 Granted 302.7 30.53 Exercised (9.3 ) 29.46 Forfeited or expired (95.9 ) 42.62 Outstanding at June 30, 2019 1,142.1 36.07 7.5 $ 2,540 Vested at June 30, 2019 628.6 38.70 6.0 $ 2,206 The aggregate intrinsic value of options exercised during the three months ended June 30, 2019 was less than $0.1 million .

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective rates used in the calculation of income taxes were 26.3% and 25.8% for the three months ended June 30, 2019 and 2018 , respectively. The increase in the effective tax rate for the three months ended June 30, 2019 versus the prior year period was primarily related to discrete items arising from stock compensation.

Employee Retirement Plans

Employee Retirement Plans	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Employee Retirement Plans	Employee Retirement Plans The primary components of Net Periodic Benefits consist of the following: Three Months Ended June 30, (In thousands) 2019 2018 Interest cost $ 577 $ 610 Expected return on assets (721 ) (768 ) Net periodic benefit income $ (144 ) $ (158 ) During the three months ended June 30, 2019 , we contributed $0.1 million to our non-qualified defined benefit plan and made no contributions to the qualified defined benefit plan. During the remainder of fiscal 2020 , we expect to contribute an additional $0.3 million to our non-qualified plan and make a $1.0 million contribution to the qualified plan.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Jun. 30, 2019
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels. During the three months ended June 30, 2019 and 2018 , approximately 44.1% and 42.6% , respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 24.2% and 24.6% , respectively, of our gross revenues for the three months ended June 30, 2019 and 2018 , respectively. The gross revenues for Walmart are included in our North American OTC Healthcare segment and Household Cleaning segment (prior to the sale of our Household Cleaning segment on July 2, 2018). Our product distribution in the United States is currently managed by a third party through one primary distribution center near St. Louis, Missouri, and we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. On May 13, 2019, we entered into an agreement with a second third party logistics provider for a warehouse, and we intend to transition to this facility, which will be managed by a new logistics provider. A serious disruption, caused by performance or contractual issues with a third party distribution manager or by earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. Any disruption as a result of business integration, transition of our distribution center to the new third party manager or new location, or third party performance at our distribution centers could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of the products associated with our acquisition of C.B. Fleet Company, Inc. ("Fleet"), which would also limit our ability to provide those products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution centers, the third party distribution managers or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At June 30, 2019 , we had relationships with 113 third party manufacturers. Of those, we had long-term contracts with 30 manufacturers that produced items that accounted for approximately 67.1% of gross sales for the three months ended June 30, 2019 . At June 30, 2018 , we had relationships with 116 third party manufacturers. Of those, we had long-term contracts with 38 manufacturers that produced items that accounted for approximately 61.9% of gross sales for the three months ended June 30, 2018 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	3 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018; see Note 2 for further information. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended June 30, 2019 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 210,784 $ 21,370 $ — $ 232,154 Cost of sales 88,811 9,276 — 98,087 Gross profit 121,973 12,094 — 134,067 Advertising and promotion 31,014 3,787 — 34,801 Contribution margin $ 90,959 $ 8,307 $ — 99,266 Other operating expenses 27,780 Operating income 71,486 Other expense 25,436 Income before income taxes 46,050 Provision for income taxes 12,125 Net income $ 33,925 * Intersegment revenues of $0.8 million were eliminated from the North American OTC Healthcare segment. Three Months Ended June 30, 2018 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 214,775 $ 19,394 $ 19,811 $ 253,980 Cost of sales 89,153 7,616 16,588 113,357 Gross profit 125,622 11,778 3,223 140,623 Advertising and promotion 33,258 3,423 430 37,111 Contribution margin $ 92,364 $ 8,355 $ 2,793 103,512 Other operating expenses 31,025 Operating income 72,487 Other expense 26,027 Income before income taxes 46,460 Benefit for income taxes 11,994 Net income $ 34,466 * Intersegment revenues of $2.7 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended June 30, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,535 $ 230 $ — $ 28,765 Cough & Cold 17,340 5,382 — 22,722 Women's Health 59,578 2,419 — 61,997 Gastrointestinal 31,572 6,985 — 38,557 Eye & Ear Care 26,753 3,011 — 29,764 Dermatologicals 25,738 690 — 26,428 Oral Care 19,979 2,652 — 22,631 Other OTC 1,289 1 — 1,290 Household Cleaning — — — — Total segment revenues $ 210,784 $ 21,370 $ — $ 232,154 Three Months Ended June 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,258 $ 157 $ — $ 28,415 Cough & Cold 16,214 5,171 — 21,385 Women's Health 63,477 2,257 — 65,734 Gastrointestinal 32,799 5,990 — 38,789 Eye & Ear Care 25,472 2,619 — 28,091 Dermatologicals 25,122 532 — 25,654 Oral Care 22,197 2,667 — 24,864 Other OTC 1,236 1 — 1,237 Household Cleaning — — 19,811 19,811 Total segment revenues $ 214,775 $ 19,394 $ 19,811 $ 253,980 Our total segment revenues by geographic area are as follows: Three Months Ended June 30, 2019 2018 United States $ 200,629 $ 223,477 Rest of world 31,525 30,503 Total $ 232,154 $ 253,980 Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: June 30, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 30,916 $ 578,309 Intangible assets Indefinite-lived 2,195,617 76,677 2,272,294 Finite-lived, net 223,961 5,103 229,064 Intangible assets, net 2,419,578 81,780 2,501,358 Total $ 2,966,971 $ 112,696 $ 3,079,667 March 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 31,190 $ 578,583 Intangible assets Indefinite-lived 2,195,617 77,574 2,273,191 Finite-lived, net 228,743 5,276 234,019 Intangible assets, net 2,424,360 82,850 2,507,210 Total $ 2,971,753 $ 114,040 $ 3,085,793

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Director Equity Grants Pursuant to the Plan, each of the independent members of the Board of Directors received a grant of 4,183 RSUs on July 30, 2019. The RSUs are fully vested upon receipt of the award and will be settled by delivery to the director of one share of our common stock for each vested RSU promptly following the earliest of (i) the director's death, (ii) the director's separation from service or (iii) a change in control of the Company.

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2020 ) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three months ended June 30, 2019 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2020 . These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update amends a number of aspects of lease accounting, including requiring lessees to recognize all leases with a term greater than one year as a right-of-use ("ROU") asset and corresponding lease liability, measured at the present value of the lease payments. On April 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for the three months ended June 30, 2019 are presented under Topic 842. No prior period amounts were adjusted and the prior period continues to be reported in accordance with previous lease guidance, ASC Topic 840, Leases . The new standard provides a number of optional practical expedients in transition. We elected the package of transition provisions available for expired or existing contracts, which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697 ) $ (5,697 ) Long-term operating lease liabilities, net of current portion $ — $ (13,296 ) $ (13,296 ) Other accrued liabilities (1) $ (60,663 ) $ 1,558 $ (59,105 ) (1) Relates to deferred rent and exit costs associated with existing leases. Adoption of this accounting pronouncement had no impact on our other financial statements. See Note 6 for our lease accounting policy. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. These amendments clarify and improve areas of guidance related to recently issued standards on the topics of credit losses, hedging and recognition and measurements. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief , which provides entities that have certain instruments an option to irrevocably elect the fair value option in Subtopic 825-10. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Business and Basis of Present_3

Business and Basis of Presentation (Tables)	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Effects of Recently Adopted Accounting Pronouncement	The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697 ) $ (5,697 ) Long-term operating lease liabilities, net of current portion $ — $ (13,296 ) $ (13,296 ) Other accrued liabilities (1) $ (60,663 ) $ 1,558 $ (59,105 ) (1) Relates to deferred rent and exit costs associated with existing leases.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) June 30, 2019 March 31, 2019 Components of Inventories Packaging and raw materials $ 14,367 $ 17,082 Work in process 342 161 Finished goods 114,679 102,637 Inventories $ 129,388 $ 119,880

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2019 Goodwill $ 711,104 $ 31,190 $ 742,294 Accumulated impairment loss (163,711 ) — (163,711 ) Balance - March 31, 2019 547,393 31,190 578,583 2020 Reductions: Effects of foreign currency exchange rates — (274 ) (274 ) Balance - June 30, 2019 Goodwill 711,104 30,916 742,020 Accumulated impairment loss (163,711 ) — (163,711 ) Balance - June 30, 2019 $ 547,393 $ 30,916 $ 578,309

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (897 ) (63 ) (960 ) Balance — June 30, 2019 2,272,294 390,220 2,662,514 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 4,906 4,906 Effects of foreign currency exchange rates — (14 ) (14 ) Balance — June 30, 2019 — 161,156 161,156 Intangible assets, net - June 30, 2019 $ 2,272,294 $ 229,064 $ 2,501,358
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (897 ) (63 ) (960 ) Balance — June 30, 2019 2,272,294 390,220 2,662,514 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 4,906 4,906 Effects of foreign currency exchange rates — (14 ) (14 ) Balance — June 30, 2019 — 161,156 161,156 Intangible assets, net - June 30, 2019 $ 2,272,294 $ 229,064 $ 2,501,358

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three months ended June 30, 2019 was as follows: (In thousands) Operating lease cost $ 1,216 Short term lease cost 23 Variable lease cost 16,599 Sublease income (914 ) Total net lease cost $ 16,924
Maturities of Operating Leases	As of June 30, 2019 , the maturities of operating lease liabilities were as follows: (In thousands) Year Ending March 31, 2020 (Remaining nine months ending March 31, 2020) $ 4,577 2021 3,450 2022 2,488 2023 1,794 2024 1,705 Thereafter 6,761 Total undiscounted lease payments 20,775 Less imputed interest (3,150 ) Total present value of lease payments $ 17,625
Future Minimum Rental Payments for Operating Leases Under Prior Guidance	The following table summarizes future minimum lease payments for our operating leases as of March 31, 2019, before adoption of ASC 842: (In thousands) Facilities Equipment Total Year Ending March 31, 2020 $ 2,828 $ 314 $ 3,142 2021 2,633 248 2,881 2022 2,265 213 2,478 2023 1,684 105 1,789 2024 1,705 — 1,705 Thereafter 6,780 — 6,780 $ 17,895 $ 880 $ 18,775

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) June 30, 2019 March 31, 2019 Accrued marketing costs $ 31,886 $ 31,228 Accrued compensation costs 5,701 10,958 Accrued broker commissions 1,057 1,361 Income taxes payable 5,640 88 Accrued professional fees 2,284 2,441 Accrued production costs 9,252 6,788 Other accrued liabilities 6,526 7,799 $ 62,346 $ 60,663

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) June 30, 2019 March 31, 2019 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024. 738,000 738,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022. 55,000 75,000 Long-term debt 1,793,000 1,813,000 Less: unamortized debt costs (13,620 ) (14,402 ) Long-term debt, net $ 1,779,380 $ 1,798,598
Aggregate Future Principal Payments	As of June 30, 2019 , aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 5.375% senior unsecured notes due 2021 (the "2013 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2020 (remaining nine months ending March 31, 2020) $ — 2021 — 2022 455,000 2023 — 2024 1,338,000 Thereafter — $ 1,793,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at June 30, 2019 and March 31, 2019 . June 30, 2019 March 31, 2019 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 627,000 $ 600,000 $ 606,000 2013 Senior Notes 400,000 403,000 400,000 401,500 2012 Term B-5 Loans 738,000 733,388 738,000 728,775 2012 ABL Revolver 55,000 55,000 75,000 75,000

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Jun. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at June 30, 2019 and March 31, 2019 : (In thousands) June 30, 2019 March 31, 2019 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (27,102 ) $ (26,878 ) Unrecognized net gain on pension plans 1,131 1,131 Accumulated other comprehensive loss, net of tax $ (25,971 ) $ (25,747 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, (In thousands, except per share data) 2019 2018 Numerator Net income $ 33,925 $ 34,466 Denominator Denominator for basic earnings per share — weighted average shares outstanding 51,697 52,640 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 350 302 Denominator for diluted earnings per share 52,047 52,942 Earnings per Common Share: Basic earnings per share $ 0.66 $ 0.65 Diluted earnings per share $ 0.65 $ 0.65

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of Restricted Shares	A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted Average Grant-Date Fair Value Three Months Ended June 30, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 203.8 29.46 Vested and issued (173.4 ) 43.00 Forfeited (31.1 ) 48.32 Vested and nonvested at June 30, 2018 392.8 36.68 Vested at June 30, 2018 90.5 29.88 Three Months Ended June 30, 2019 Vested and nonvested at March 31, 2019 413.0 $ 36.58 Granted 195.2 30.55 Vested and issued (61.8 ) 48.04 Forfeited (25.2 ) 36.85 Vested and nonvested at June 30, 2019 521.2 32.94 Vested at June 30, 2019 113.2 31.05
Fair Value of Options Granted	The weighted average grant-date fair values of the options granted during the three months ended June 30, 2019 and 2018 were $10.83 and $10.22 , respectively. Three Months Ended June 30, 2019 2018 Expected volatility 30.9% - 31.3% 29.6 % Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 Risk-free rate 2.3% to 2.4% 2.9 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Three Months Ended June 30, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (32.8 ) 26.81 Forfeited or expired (72.7 ) 45.00 Outstanding at June 30, 2018 1,062.2 38.61 7.6 $ 6,573 Vested at June 30, 2018 599.8 37.99 6.2 $ 4,054 Three Months Ended June 30, 2019 Outstanding at March 31, 2019 944.6 $ 38.45 Granted 302.7 30.53 Exercised (9.3 ) 29.46 Forfeited or expired (95.9 ) 42.62 Outstanding at June 30, 2019 1,142.1 36.07 7.5 $ 2,540 Vested at June 30, 2019 628.6 38.70 6.0 $ 2,206

Employee Retirement Plans (Tabl

Employee Retirement Plans (Tables)	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Primary Components of Net Periodic Benefits	The primary components of Net Periodic Benefits consist of the following: Three Months Ended June 30, (In thousands) 2019 2018 Interest cost $ 577 $ 610 Expected return on assets (721 ) (768 ) Net periodic benefit income $ (144 ) $ (158 )

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended June 30, 2019 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 210,784 $ 21,370 $ — $ 232,154 Cost of sales 88,811 9,276 — 98,087 Gross profit 121,973 12,094 — 134,067 Advertising and promotion 31,014 3,787 — 34,801 Contribution margin $ 90,959 $ 8,307 $ — 99,266 Other operating expenses 27,780 Operating income 71,486 Other expense 25,436 Income before income taxes 46,050 Provision for income taxes 12,125 Net income $ 33,925 * Intersegment revenues of $0.8 million were eliminated from the North American OTC Healthcare segment. Three Months Ended June 30, 2018 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 214,775 $ 19,394 $ 19,811 $ 253,980 Cost of sales 89,153 7,616 16,588 113,357 Gross profit 125,622 11,778 3,223 140,623 Advertising and promotion 33,258 3,423 430 37,111 Contribution margin $ 92,364 $ 8,355 $ 2,793 103,512 Other operating expenses 31,025 Operating income 72,487 Other expense 26,027 Income before income taxes 46,460 Benefit for income taxes 11,994 Net income $ 34,466 * Intersegment revenues of $2.7 million were eliminated from the North American OTC Healthcare segment.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended June 30, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,535 $ 230 $ — $ 28,765 Cough & Cold 17,340 5,382 — 22,722 Women's Health 59,578 2,419 — 61,997 Gastrointestinal 31,572 6,985 — 38,557 Eye & Ear Care 26,753 3,011 — 29,764 Dermatologicals 25,738 690 — 26,428 Oral Care 19,979 2,652 — 22,631 Other OTC 1,289 1 — 1,290 Household Cleaning — — — — Total segment revenues $ 210,784 $ 21,370 $ — $ 232,154 Three Months Ended June 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,258 $ 157 $ — $ 28,415 Cough & Cold 16,214 5,171 — 21,385 Women's Health 63,477 2,257 — 65,734 Gastrointestinal 32,799 5,990 — 38,789 Eye & Ear Care 25,472 2,619 — 28,091 Dermatologicals 25,122 532 — 25,654 Oral Care 22,197 2,667 — 24,864 Other OTC 1,236 1 — 1,237 Household Cleaning — — 19,811 19,811 Total segment revenues $ 214,775 $ 19,394 $ 19,811 $ 253,980
Information about our Segment Revenues by Geographic Area	Our total segment revenues by geographic area are as follows: Three Months Ended June 30, 2019 2018 United States $ 200,629 $ 223,477 Rest of world 31,525 30,503 Total $ 232,154 $ 253,980
Information about our Consolidated Goodwill and Intangible Assets Allocated to Reportable Segments	Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: June 30, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 30,916 $ 578,309 Intangible assets Indefinite-lived 2,195,617 76,677 2,272,294 Finite-lived, net 223,961 5,103 229,064 Intangible assets, net 2,419,578 81,780 2,501,358 Total $ 2,966,971 $ 112,696 $ 3,079,667 March 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 31,190 $ 578,583 Intangible assets Indefinite-lived 2,195,617 77,574 2,273,191 Finite-lived, net 228,743 5,276 234,019 Intangible assets, net 2,424,360 82,850 2,507,210 Total $ 2,971,753 $ 114,040 $ 3,085,793

Business and Basis of Present_4

Business and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	May 13, 2019	Apr. 01, 2019	Mar. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Nonoperating Income (Expense)	$ (416)	$ (87)
Operating lease right-of-use asset	16,097		$ 20,500	$ 17,435	$ 0
Operating lease liabilities, current portion	(5,099)			(5,697)	0
Long-term operating lease liability, net of current portion	(12,526)			(13,296)	0
Other accrued liabilities				(59,105)	$ (60,663)
Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Nonoperating Income (Expense)	$ (1,000)
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use asset				17,435
Operating lease liabilities, current portion				(5,697)
Long-term operating lease liability, net of current portion				(13,296)
Other accrued liabilities				$ (1,558)

Divestitures (Details)

Divestitures (Details) - Household Cleaning - Divestiture $ in Millions	Jul. 02, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from disposal	$ 65.9
Pre-tax gain on divestiture	$ 1.3

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 14,367	$ 17,082
Work in process	342	161
Finished goods	114,679	102,637
Inventories	129,388	119,880
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5,600	$ 5,500

Goodwill (Details)

Goodwill (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2019USD ($)
Goodwill [Line Items]
Goodwill	$ 742,294
Accumulated impairment loss	(163,711)
Goodwill, net	578,583
Effects of foreign currency exchange rates	(274)
Goodwill	742,020
Accumulated impairment loss	(163,711)
Goodwill, net	578,309
North American OTC Healthcare
Goodwill [Line Items]
Goodwill	711,104
Accumulated impairment loss	(163,711)
Goodwill, net	547,393
Effects of foreign currency exchange rates	0
Goodwill	711,104
Accumulated impairment loss	(163,711)
Goodwill, net	547,393
International OTC Healthcare
Goodwill [Line Items]
Goodwill	31,190
Accumulated impairment loss	0
Goodwill, net	31,190
Effects of foreign currency exchange rates	(274)
Goodwill	30,916
Accumulated impairment loss	0
Goodwill, net	$ 30,916

Intangible Assets, net (Schedul

Intangible Assets, net (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance	$ 2,273,191
Indefinite-lived trademarks, ending balance	2,272,294
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance	2,663,474
Totals, gross, effects of foreign currency exchange rate	(960)
Totals, gross, ending balance	2,662,514
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance	156,264
Accumulated amortization, additions	4,906	$ 5,800
Accumulated amortization, effects of foreign exchange rates	(14)
Accumulated amortization, ending balance	161,156
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	229,064		$ 234,019
Intangible Assets, Net [Abstract]
Intangible assets, net	2,501,358		$ 2,507,210
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance	390,283
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate	(63)
Finite-lived trademarks and customer relationships, ending balance	390,220
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance	156,264
Accumulated amortization, additions	4,906
Accumulated amortization, effects of foreign exchange rates	(14)
Accumulated amortization, ending balance	161,156
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	229,064
Indefinite-Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance	2,273,191
Indefinite lived trademarks, effects of foreign currency exchange rate	(897)
Indefinite-lived trademarks, ending balance	$ 2,272,294

Intangible Assets, net (Narrati

Intangible Assets, net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 4,906	$ 5,800
Remainder of the year	14,700
2021	19,600
2022	19,600
2023	19,600
2024	19,600
Thereafter	$ 135,900

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	May 31, 2019	May 13, 2019	Apr. 01, 2019	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Term of contract		5 years
Renewal term		5 years
Weighted average remaining lease term	6 years 2 months 27 days
Weighted average discount rate	5.21%
Operating lease right-of-use asset	$ 16,097		$ 20,500	$ 17,435	$ 0
Operating lease liability	$ 17,625		$ 20,500
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	10 years
Renewal term	6 years

Leases (Operating Lease Cost) (

Leases (Operating Lease Cost) (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 1,216
Short term lease cost	23
Variable lease cost	16,599
Sublease income	(914)
Total net lease cost	$ 16,924

Leases (Operating Lease Maturit

Leases (Operating Lease Maturities) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	May 13, 2019
Leases [Abstract]
2020 (Remaining nine months ending March 31, 2020)	$ 4,577
2021	3,450
2022	2,488
2023	1,794
2024	1,705
Thereafter	6,761
Total undiscounted lease payments	20,775
Less imputed interest	(3,150)
Total present value of lease payments	$ 17,625	$ 20,500

Leases (Lease Maturities Under

Leases (Lease Maturities Under Prior Guidance) (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Leased Assets [Line Items]
2020	$ 3,142
2021	2,881
2022	2,478
2023	1,789
2024	1,705
Thereafter	6,780
Total	18,775
Facilities
Operating Leased Assets [Line Items]
2020	2,828
2021	2,633
2022	2,265
2023	1,684
2024	1,705
Thereafter	6,780
Total	17,895
Equipment
Operating Leased Assets [Line Items]
2020	314
2021	248
2022	213
2023	105
2024	0
Thereafter	0
Total	$ 880

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Payables and Accruals [Abstract]
Accrued marketing costs	$ 31,886	$ 31,228
Accrued compensation costs	5,701	10,958
Accrued broker commissions	1,057	1,361
Income taxes payable	5,640	88
Accrued professional fees	2,284	2,441
Accrued production costs	9,252	6,788
Other accrued liabilities	6,526	7,799
Total other accrued liabilities	$ 62,346	$ 60,663

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 1,779,380,000	$ 1,798,598,000
2016 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
2013 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 55,000,000
Line of credit facility, additional borrowing capacity	$ 102,700,000

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,793,000	$ 1,813,000
Less: unamortized debt costs	(13,620)	(14,402)
Long-term debt, net	1,779,380	1,798,598
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)	55,000	75,000
Long-term debt, net	$ 55,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%
Total long-term debt (including current portion)	$ 400,000	400,000
Term B-5 Loans | 2012 Senior Notes
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 738,000	$ 738,000
Term B-5 Loans | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.00%
Debt instrument, variable rate, minimum (as percent)	0.00%
Term B-5 Loans | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	1.00%
Debt instrument, variable rate, minimum (as percent)	1.00%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Aggregate Future Principal Payments
2020 (remaining nine months ending March 31, 2020)	$ 0
2021	0
2022	455,000
2023	0
2024	1,338,000
Thereafter	0
Total long-term debt (including current portion)	$ 1,793,000	$ 1,813,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Senior Notes | 2016 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 600,000	$ 600,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	738,000	738,000
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	55,000	75,000
Fair Value, Measurements, Recurring | Senior Notes | 2016 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	627,000	606,000
Fair Value, Measurements, Recurring | Senior Notes | 2013 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	403,000	401,500
Fair Value, Measurements, Recurring | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	733,388	728,775
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 55,000	$ 75,000

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended
	Jun. 30, 2019USD ($)vote$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2019$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0
Stock repurchased during period (in shares) | shares	949,825	1,449,750
Stock acquired, average cost per share (in USD per share) | $ / shares	$ 30.29	$ 34.47
Treasury stock acquired | $	$ 29,565,000	$ 52,259,000
Restricted Shares
Class of Stock [Line Items]
Stock repurchased during period (in shares) | shares	26,264	68,939
Stock acquired, average cost per share (in USD per share) | $ / shares	$ 30.44	$ 33.09
Treasury stock acquired | $	$ 28,800,000	$ 50,000,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ 1,101,623,000	$ 1,095,831,000	$ 1,161,723,000	$ 1,178,610,000
Reclassification from accumulated other comprehensive loss into earnings	0	0
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	(27,102,000)	(26,878,000)
Unrecognized net gain on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	1,131,000	1,131,000
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ (25,971,000)	$ (25,747,000)	$ (22,289,000)	$ (19,315,000)

Earnings Per Share (Computation

Earnings Per Share (Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Numerator
Net income	$ 33,925	$ 34,466
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	51,697	52,640
Dilutive effect of nonvested restricted stock units and options issued to employees and directors (in shares)	350	302
Denominator for diluted earnings per share (in shares)	52,047	52,942
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 0.66	$ 0.65
Diluted earnings per share (in USD per share)	$ 0.65	$ 0.65

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1	0.8

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	May 13, 2019	May 06, 2019	May 31, 2014	Jun. 30, 2014	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation, Aggregate Disclosures:
Maximum number of shares per participant, 12 month period (in shares)			1,000,000	2,500,000
Extension of plan term				10 years
Share-based compensation costs charged against income					$ 1,400	$ 1,700
Tax benefit recognized from share-based compensation expense					200	200
Unrecognized compensation costs related to nonvested awards					$ 11,000
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition					1 year 1 month 6 days
Total fair value of vested shares					$ 6,100	10,700
Proceeds from exercise of stock options					275	880
Tax benefit realized from exercise of stock options					$ 400	$ 1,200
Shares available for issuance under the Plan (in shares)					1,400,000
Stock options granted (in shares)					302,700	294,500
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share)					$ 10.83	$ 10.22
Options exercised, aggregate intrinsic value					$ 100
Performance Shares
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)		98,644
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)	7,287	89,286			195,200	203,800
Restricted Stock Units (RSUs) | Employee
Restricted Shares
Award vesting period					3 years
Restricted Stock Units (RSUs) | Employee | Maximum
Restricted Shares
Award vesting period					3 years
Restricted Stock Units (RSUs) | Director
Restricted Shares
Number of common shares into which each RSU may be converted (in shares)					1
Period following director's term in which RSUs may be settled					6 months
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)	21,194	281,487
Stock options granted, exercise price (in USD per share)	$ 30.19	$ 30.56
Stock Options | Minimum
Restricted Shares
Award vesting period					3 years
Stock Options | Maximum
Restricted Shares
Award vesting period					5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant					10 years
Long-term Equity Incentive Plan, 2005
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)			5,000,000
Number of additional shares authorized (in shares)				1,800,000

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	May 13, 2019	May 06, 2019	Jun. 30, 2019	Jun. 30, 2018
Shares
Outstanding, beginning of period (in shares)			413,000	393,500
Granted (in shares)	7,287	89,286	195,200	203,800
Vested and issued (in shares)			(61,800)	(173,400)
Forfeited (in shares)			(25,200)	(31,100)
Outstanding, end of period (in shares)			521,200	392,800
Vested, end of period (in shares)			113,200	90,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 36.58	$ 44.13
Granted, weighted-average grant-date fair value (in USD per share)			30.55	29.46
Vested and issued, weighted-average grant-date fair value (in USD per share)			48.04	43
Forfeited, weighted-average grant-date fair value (in USD per share)			36.85	48.32
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			32.94	36.68
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 31.05	$ 29.88
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Director
Weighted Average Grant-Date Fair Value
Period following director's term in which RSUs may be settled			6 months
Maximum | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		29.60%
Expected dividends	$ 0	$ 0
Expected term in years		6 years
Risk-free rate		2.90%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award exercisability period, from date of grant	10 years
Expected volatility	31.30%
Expected term in years	7 years
Risk-free rate	2.40%
Award vesting period	5 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.90%
Expected term in years	6 years
Risk-free rate	2.30%
Award vesting period	3 years

Share-Based Compensation (Sto_2

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Shares
Outstanding, beginning of period (in shares)	944,600	873,200
Granted (in shares)	302,700	294,500
Exercised (in shares)	(9,300)	(32,800)
Forfeited or expired (in shares)	(95,900)	(72,700)
Outstanding, end of period (in shares)	1,142,100	1,062,200
Exercisable, end of period (in shares)	628,600	599,800
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 38.45	$ 41.79
Granted, weighted-average exercise price (in USD per share)	30.53	29.46
Exercised, weighted-average exercise price (in USD per share)	29.46	26.81
Forfeited or expired, weighted-average exercise price (in USD per share)	42.62	45
Outstanding, end of period, weighted-average exercise price (in USD per share)	36.07	38.61
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 38.70	$ 37.99
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 6 months	7 years 7 months 6 days
Exercisable, end of period, weighted-average remaining contractual term	6 years	6 years 2 months 12 days
Outstanding, end of period, aggregate intrinsic value	$ 2,540	$ 6,573
Exercisable, end of period, aggregate intrinsic value	$ 2,206	$ 4,054

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	26.30%	25.80%

Employee Retirement Plans (Expe

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement [Abstract]
Interest cost	$ 577	$ 610
Expected return on assets	(721)	(768)
Net periodic benefit income	$ (144)	$ (158)

Employee Retirement Plans (Narr

Employee Retirement Plans (Narrative) (Details)	3 Months Ended
	Jun. 30, 2019USD ($)
Non-qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	$ 100,000
Expected employer contributions, remainder of fiscal year	300,000
Qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	0
Expected employer contributions, remainder of fiscal year	$ 1,000,000

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Concentration Risk [Line Items]
Number of third-party manufacturers	113	116
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	24.20%	24.60%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	67.10%	61.90%
Number of third-party manufacturers with long-term contracts	30	38
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	44.10%	42.60%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information, Profit (Loss):
Total revenues	$ 232,154	$ 253,980
Cost of sales	98,087	113,357
Gross profit	134,067	140,623
Advertising and promotion	34,801	37,111
Contribution margin	99,266	103,512
Other operating expenses	27,780	31,025
Operating income	71,486	72,487
Other expense	25,436	26,027
Income before income taxes	46,050	46,460
Provision for income taxes	12,125	11,994
Net income	33,925	34,466
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	210,784	214,775
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	21,370	19,394
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	19,811
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	210,784	214,775
Cost of sales	88,811	89,153
Gross profit	121,973	125,622
Advertising and promotion	31,014	33,258
Contribution margin	90,959	92,364
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	21,370	19,394
Cost of sales	9,276	7,616
Gross profit	12,094	11,778
Advertising and promotion	3,787	3,423
Contribution margin	8,307	8,355
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	19,811
Cost of sales	0	16,588
Gross profit	0	3,223
Advertising and promotion	0	430
Contribution margin	0	2,793
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 800	$ 2,700

Business Segments (Revenue) (De

Business Segments (Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 232,154	$ 253,980
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,765	28,415
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,722	21,385
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	61,997	65,734
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,557	38,789
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,764	28,091
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,428	25,654
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,631	24,864
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,290	1,237
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	19,811
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	210,784	214,775
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,535	28,258
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	17,340	16,214
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	59,578	63,477
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	31,572	32,799
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,753	25,472
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,738	25,122
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	19,979	22,197
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,289	1,236
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	21,370	19,394
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	230	157
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,382	5,171
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,419	2,257
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,985	5,990
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,011	2,619
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	690	532
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,652	2,667
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1	1
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	19,811
Household Cleaning | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0
Household Cleaning | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 0	$ 19,811

Business Segments (Revenue by G

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 232,154	$ 253,980
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	200,629	223,477
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 31,525	$ 30,503

Business Segments (Goodwill and

Business Segments (Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 578,309	$ 578,583
Intangible assets
Indefinite-lived	2,272,294	2,273,191
Finite-lived, net	229,064	234,019
Intangible assets, net	2,501,358	2,507,210
Total	3,079,667	3,085,793
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	547,393	547,393
Intangible assets
Indefinite-lived	2,195,617	2,195,617
Finite-lived, net	223,961	228,743
Intangible assets, net	2,419,578	2,424,360
Total	2,966,971	2,971,753
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	30,916	31,190
Intangible assets
Indefinite-lived	76,677	77,574
Finite-lived, net	5,103	5,276
Intangible assets, net	81,780	82,850
Total	$ 112,696	$ 114,040

Subsequent Events (Details)

Subsequent Events (Details) - Restricted Stock Units (RSUs) - shares	Jul. 30, 2019	May 13, 2019	May 06, 2019	Jun. 30, 2019	Jun. 30, 2018
Subsequent Event [Line Items]
Granted (in shares)		7,287	89,286	195,200	203,800
Subsequent Event
Subsequent Event [Line Items]
Granted (in shares)	4,183
Director
Subsequent Event [Line Items]
Number of common shares into which each RSU may be converted (in shares)				1
Director | Subsequent Event
Subsequent Event [Line Items]
Number of common shares into which each RSU may be converted (in shares)	1

Uncategorized Items - pbh10qjun

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000